World's Best Scientists 2026 revealed!

John W. Park publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John W. Park sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

John W. Park D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John W. Park sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

John W. Park is affiliated with the University of California, San Francisco in the United States. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant emphasis on Oncology and Cancer Research as subfields.

The scientist's work addresses topics related to cancer biology and clinical treatment, including:

  • Cancer Cells and Metastasis
  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • Advanced Breast Cancer Therapies
  • Lung Cancer Treatments and Mutations
  • BRCA gene mutations in cancer
  • Bone health and treatments

John W. Park has contributed to several peer-reviewed publications. Some notable recent papers include:

  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer, 2020, JAMA Oncology
  • Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy, 2020, JNCI Journal of the National Cancer Institute
  • Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab, 2020, Clinical Cancer Research
  • Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid, 2021, npj Breast Cancer
  • A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression, 2020, Journal of Clinical Oncology

Their publications have appeared in the following frequent venues:

  • npj Breast Cancer
  • JAMA Oncology
  • JNCI Journal of the National Cancer Institute
  • Clinical Cancer Research
  • Journal of Clinical Oncology

John W. Park frequently collaborates with other researchers. Regular co-authors include:

  • Hope S. Rugo
  • Mark Jesus M. Magbanua
  • A. Jo Chien
  • Michelle Melisko
  • Laura J. Esserman

Best Publications

  • Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

    Teri N. Kreisl;Lyndon Kim;Kraig Moore;Paul Duic

  • Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

    Dmitri B. Kirpotin;Daryl C. Drummond;Yi Shao;M. Refaat Shalaby

  • Identification of heregulin, a specific activator of p185erbB2.

    William E. Holmes;Mark X. Sliwkowski;Robert W. Akita;William J. Henzel

  • Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

    John W Park;Keelung Hong;Dmitri B Kirpotin;Gail Colbern

  • Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

    Hope S. Rugo;Roy S. Herbst;Glenn Liu;John W. Park

  • The cancer glycocalyx mechanically primes integrin-mediated growth and survival

    Matthew J. Paszek;Christopher C. DuFort;Olivier Rossier;Russell O Bainer

  • STERICALLY STABILIZED ANTI-HER2 IMMUNOLIPOSOMES : DESIGN AND TARGETING TO HUMAN BREAST CANCER CELLS IN VITRO

    Dmitri Kirpotin;John W. Park;Keelung Hong;Samuel Zalipsky

  • Liposome-based drug delivery in breast cancer treatment.

    John W Park

  • Subtype and pathway specific responses to anticancer compounds in breast cancer.

    Laura M. Heiser;Anguraj Sadanandam;Wen-Lin Kuo;Stephen C. Benz

  • Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs In vivo

    Christoph Mamot;Daryl C. Drummond;Charles O. Noble;Verena Kallab

  • Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRvIII-overexpressing Tumor Cells

    Christoph Mamot;Daryl C Drummond;Udo Greiser;Keelung Hong

  • Tumor targeting using anti-her2 immunoliposomes

    J.W. Park;D.B. Kirpotin;K. Hong;R. Shalaby

  • Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

    Daryl C. Drummond;Charles O. Noble;Zexiong Guo;Keelung Hong

  • Development of anti-p185HER2 immunoliposomes for cancer therapy.

    J W Park;K Hong;P Carter;H Asgari

  • Adaptive Randomization of Neratinib in Early Breast Cancer

    John W Park;Minetta C Liu;Douglas Yee;Christina Yau

  • Immunoliposomes that optimize internalization into target cells

    Christopher C. Benz;Demetrios P. Papahadjopoulos;John W. Park;Keelung Hong

  • Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

    Glenn Liu;Hope S. Rugo;George Wilding;Teresa M. McShane

  • Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

    Daryl C. Drummond;Charles O. Noble;Mark E. Hayes;John W. Park

  • Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo.

    Kevin C. Weng;Charles O. Noble;Brigitte Papahadjopoulos-Sternberg;Fanqing F. Chen

  • Circulating Tumor Cells

    Mark Jesus M. Magbanua;John W. Park

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Christopher C. Benz
Christopher C. Benz Buck Institute for Research on Aging
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Krystof S. Bankiewicz
Krystof S. Bankiewicz The Ohio State University
James D. Marks
James D. Marks University of California, San Francisco
Christina Yau
Christina Yau University of California, San Francisco
Mitchel S. Berger
Mitchel S. Berger University of California, San Francisco
Andrei Goga
Andrei Goga University of California, San Francisco
Donald A. Berry
Donald A. Berry The University of Texas MD Anderson Cancer Center
Dan H. Moore
Dan H. Moore University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in healthcare doesn’t have to mean going to medical school. There are a variety of online degrees that can open the door to in-demand roles in the industry, often with flexible and affordable options.

For students interested in healthcare leadership, pursuing one of the cheapest mha programs online can lead to management jobs in hospitals, clinics, and health organizations. If advanced nursing is your goal, many professionals are now choosing the least expensive dnp programs to become nurse practitioners or healthcare policy leaders.

Pharmacy is another growing field, and those looking for advanced practice credentials can explore online pharm d programs designed with working students in mind. Meanwhile, for those interested in technology, administration, and patient data, rhia certification programs online offer pathways to manage the flow of health information in modern systems.

These programs offer new career pathways for those seeking flexibility, affordability, or new roles in the healthcare sector.

Best Scientists Citing John W. Park

Trending Scientists

Recently Published Articles